Yohimbine is a potent and relatively nonselective ␣ 2 -adrenergic receptor (AR) antagonist. In an earlier report, we demonstrated that dimeric yohimbine analogs containing methylene and methylene-diglycine tethers were highly selective human ␣ 2C -AR ligands. Little work has been done to examine the role of the tether group or the absence of the second yohimbine pharmacophore on selectivity for human ␣ 2 -AR subtypes. The goal of our study was to determine the binding affinities and functional subtype selectivities of a series of tethered yohimbine ligands in the absence of the second pharmacophore. The profiles of pharmacological activity for the yohimbine analogs on the three human ␣ 2 -AR subtypes expressed in Chinese hamster ovary cells were examined using receptor binding and cAMP inhibition assays. All of the tethered yohimbine analogs exhibited higher binding affinities at the ␣ 2C -versus ␣ 2A -and ␣ 2B -AR subtypes. Notably, the benzyl carboxy alkyl amine and the carboxy alkyl amine analogs exhibited 43-and 1995-fold and 295-and 54-fold selectivities in binding to the ␣ 2C -versus ␣ 2A -and ␣ 2B -ARs, respectively. Data from luciferase reporter gene assays confirmed the functional antagonist activities and selectivity profiles of selected compounds from the tethered series. The data demonstrate that the second pharmacophore may not be essential to obtain ␣ 2C -AR subtype selectivity, previously observed with the dimers. Further changes in the nature of the tether will help in optimization of the structureactivity relationship to obtain potent and selective ␣ 2C -AR ligands. These compounds may be used as pharmacological probes and in the treatment of human disorders.
Efforts made toward understanding the biological significance of each of the ␣ 2 -adrenergic receptor (AR) subtypes (␣ 2A , ␣ 2B , and ␣ 2C ) (Bylund et al., 1998) have resulted only in marginal success because of the lack of subtype-selective ligands. In recent years, this endeavor has been greatly assisted by genetic manipulation using mice with deletions, mutations, or overexpression of specific ␣ 2 -AR subtypes. The role of the ␣ 2C -AR, in addition to the ␣ 2A -AR, in the feedback control of neurotransmitter release is a finding from one such study (Hein et al., 1999) . Contribution of the ␣ 2C -ARs to ␣ 2 -AR opioid synergy induced by certain agonists such as moxonidine is another finding (Fairbanks et al., 2002) , suggesting that the ␣ 2C -AR may represent a better therapeutic target for analgesic therapy than the ␣ 2A -AR, since use of this subtype would also lead to fewer sedative effects. Peterhoff et al. (2003) used knockout mice to report that the ␣ 2A -and ␣ 2C -ARs mediate epinephrine-induced inhibition of insulin secretion in pancreatic islet cells. In the central nervous system, the ␣ 2C -ARs seem to have a distinct inhibitory role in various central nervous system-mediated behavioral and physiological responses including startle reactivity, aggressive behavior, and amphetamine-induced locomotor hyperactivity (Scheinin et al., 2001) . Thus, increased ␣ 2C -AR activity may lead to or result from a constitutively stressful state, thereby causing depression, which suggests that ␣ 2C -AR subtype-selective drugs may be useful in a variety of neuropsychiatric disorders (Scheinin et al., 2001) . Besides these findings derived from gene-targeted mice, a recent study (Chotani et al., 2000) has provided yet another potential therapeutic use for an ␣ 2C -AR antagonist. The study showed that at lower temperatures, the ␣ 2C -ARs are principally responsible for mediating the cold-induced augmented vasoconstrictor response. This subtype, however, did not contribute to ␣ 2 -AR-dependent vasoconstriction at 37°C. A selective inhibition of the ␣ 2C -ARs in microvessels has, thus, been proposed to provide an effective treatment for cold-induced cutaneous arterial blood vessel constriction as observed in Raynaud's phenomenon.
The increasing number of potential therapeutic uses has greatly stimulated interest in the design of ligands that interact selectively with the ␣ 2C -ARs. Lalchandani et al. (2002) have shown that dimers of the ␣ 2 -AR subtype nonselective antagonist ligand yohimbine exhibited selectivity for the ␣ 2C -AR. The n ϭ 3 and n ϭ 24 dimers exhibited the greatest ␣ 2C -AR selectivity in the series tested. Interestingly, none of the analogs surpassed the affinity of the parent compound, yohimbine. In addition, the exact mechanism underlying the ␣ 2C -AR selectivity observed for these dimeric compounds is unclear. An attempt to assess the role of the second pharmacophore and the spacer arm in the potency of dimeric ligands was recently made by Mustafa et al. (2005) . To achieve this, a monomeric tethered ligand versus a dimeric ligand approach was used. Compounds having only one pharmacophore, i.e., only one yohimbine molecule, to which side chains of varying length and containing different patterns of hydrogen bond donors/acceptors, rigidity, hydrophobicity and/or charge had been appended, were evaluated for binding to the ␣ 2C -ARs. The data showed that even in the absence of the second pharmacophore, the tethered yohimbine analogs displayed high binding affinities at the ␣ 2C -AR.
In our study, our aims were to 1) determine the affinities of the tethered yohimbine ligands at all three ␣ 2 -ARs and examine subtype selectivities exhibited, if any, by the compounds and 2) elucidate the underlying physicochemical basis for the observed ␣ 2 -AR subtype selectivities. To start with, we have evaluated the standards for this study viz. the parent compound, yohimbine, and the n ϭ 3 analog from the dimer series at the ␣ 2 -ARs. Furthermore, we have examined tethered analogs of yohimbine, which consist of various substitutions at the C-16 carbonyl position of yohimbine and yohimbinic acid (a nontethered analog of yohimbine possessing an acid functional group instead of a methyl ester at the C-16 position) at ␣ 2 -AR subtypes. The subtypes were stably expressed as homogeneous populations in Chinese hamster ovary (CHO) cells. Selected compounds were tested for binding affinities at ␣ 1 -AR subtypes, stably expressed as homogeneous populations in human embryonic kidney (HEK293) cells. Finally, functional activities of selected compounds were determined in CHO cells expressing the ␣ 2A -and ␣ 2C -ARs using a cAMP response element-luciferase (CRE-LUC) reporter gene assay. , TN) . The procedures for synthesis of the tethered yohimbine analogs and the n ϭ 3 yohimbine dimer are as described by Mustafa et al. (2005) , Zheng et al. (2000) , and Zheng (1999) . Solutions of the n ϭ 3 yohimbine dimer were prepared as described previously (Lalchandani et al., 2002) . Yohimbinic acid (2) and all the tethered yohimbine analogs, with the exception of the alkyl amine analog (8) and the carboxy alkyl amine analog (10), were dissolved in a mixture of water and dimethyl sulfoxide. Yohimbine (1), the alkyl amine analog (8), and the carboxy alkyl amine analog (10) were dissolved in water alone. Stock solutions (10 Ϫ2 M) were prepared and diluted in water to appropriate concentrations for the studies. Cell Culture. CHO cells stably expressing homogeneous populations of ␣ 2A -, ␣ 2B -, and ␣ 2C -ARs were grown in 150 cm 2 Corning flasks with Ham's F-12 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, penicillin (100 units/ml), streptomycin (100 g/ml), and Geneticin (100 g/ml). The flasks were incubated at 37°C (5% CO 2 ). Media were changed every 48 h until the cells were confluent. Upon confluence, the cells were detached by trypsin (0.05% trypsin EDTA, 5 min).
Materials and Methods

Sources of
HEK293 cells stably expressing homogeneous populations of ␣ 1A -, ␣ 1B -, and ␣ 1D -ARs were grown in 150 cm 2 Corning flasks with Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM glutamine, penicillin (100 units/ml), streptomycin (100 g/ml), and Geneticin (100 g/ml). The flasks were incubated at 37°C (5% CO 2 ). Media were changed every 48 h until the cells were confluent. Upon confluence, the cells were detached by gentle scraping.
Radioligand Binding Assays. Radioligand binding studies were conducted in intact CHO cells expressing homogeneous populations of ␣ 2A -, ␣ 2B -, and ␣ 2C -ARs. Similar studies were performed in intact HEK293 cells expressing homogeneous populations of ␣ 1A -, ␣ 1B -, and ␣ 1D -ARs. In brief, CHO cells were harvested using Ham's F-12 media after trypsinization, whereas HEK293 cells were detached by simple scraping. Detached cells were washed and centrifuged with Tris-EDTA buffer, pH 7.4; containing 50 mM Tris, 20 mM disodium EDTA, and 154 mM NaCl, in which they were finally suspended. Competition binding assays were performed in duplicate by incubating 50,000 cells with [
3 H]rauwolscine (0.1 Ci, 0.7 nM) for human ␣ 2A -, ␣ 2B -, and ␣ 2C -ARs and [
3 H]prazosin (0.1 Ci, 0.7 nM) for human ␣ 1A -, ␣ 1B -, and ␣ 1D -ARs and varying concentrations of the analogs under investigation in a water bath at 37°C. The assays were conducted in a final volume of 2 ml. Nonspecific binding was determined in the presence of 10 M phentolamine. Incubations were terminated at 60 min by rapid filtration over GF/C glass fiber filters (Whatman, Maidstone, UK) using a cell harvester (Brandel Inc., Gaithersburg, MD). The filter discs were washed three times with Tris-EDTA buffer, pH 7.4, at 4°C. The radioactivity was quantified by using a Packard Tri-Carb 2900 TR liquid scintillation analyzer (Packard Instrument Company, Meridian, CT) , and data were analyzed using GraphPad Prism (GraphPad Software Inc., San Diego, CA). The displacement curves were plotted using a standard slope factor of 1.0; and the K i values of the competing ligands were determined using the equation of Cheng and Prusoff (1973) . The percentage of specific binding in the inhibition experiments was determined by dividing the difference between the total bound (disintegrations per minute) and nonspecific bound (disintegrations per minute) by the total bound (disintegrations per minute).
Scatchard analyses were carried out using varying concentrations, ranging from 0.03 to 3.6 nM, of selected radioligands to determine their affinities (K d ) and maximal binding characteristics (B max 3 H]prazosin to human ␣ 1A -, ␣ 1B -, and ␣ 1D -ARs was conducted in a final volume of 1 ml. Nonspecific binding for the ␣ 1 -and ␣ 2 -ARs was determined in the presence of 10 M phentolamine and 10 M yohimbine, respectively. The total and nonspecific binding for each concentration was determined in triplicate. The specific binding, at each concentration of the radioligand, was established and plotted as bound ligand versus bound/free ligand and the correspond- cAMP Response Element-Luciferase Reporter Gene Assay. To verify that the observed binding affinities of yohimbine and its selected analogs correlate with the functional responses in the ␣ 2 -ARs, functional responses of selected ligands were determined by using six copies of a cAMP response element-luciferase reporter gene construct (6 CRE-LUC, pADneo2-C6-BGL). The reporter gene assays were conducted in CHO cells expressing the human ␣ 2A -and ␣ 2C -AR subtypes. The cells were grown to confluence, upon which they were isolated and electroporated in the presence of the plasmid. The transfection procedure used was the same as that described previously in CHO cells (Vansal and Feller, 1999; Lalchandani et al., 2002) . Cells were transiently transfected with the 6 CRE-LUC plasmid (5 g/100 l of cell suspension) using electroporation at 150 V, 70 ms, single pulse. Transfected cells were plated into a 96-well microplate at a density of approximately 50,000 cells per well and allowed to grow for 20 h. Fixed concentrations of the nonselective ␣ 2 -AR agonist medetomidine (Virtanen et al., 1988) (0.01 and 1 M for the ␣ 2A -and ␣ 2C -ARs, respectively), which produced a submaximal inhibition of the forskolin response, were added directly to the medium 20 min before the addition of forskolin (3-5 M) and then allowed to incubate for 4 h. Selected ligands were tested for antagonist activity and added 20 min before the addition of medetomidine. The media were then aspirated, the cells were lysed, and the luciferase activity was determined using the LucLite assay kit (Packard Biosciences, Meriden, CT). Changes in light production were measured on a Packard Topcount Luminescence Counter (Packard Biosciences) after addition of luciferin. Medetomidine inhibited the forskolin-induced cAMP changes by ϳ50 to 70% in each of the two subtypes, and the antagonist effects of yohimbine and its selected analogs were determined by their ability to reverse the medetomidine action. The IC 50 values of yohimbine and its analogs for the concentration-dependent reversal of the medetomidine action against forskolin-induced cAMP responses at the human ␣ 2C -AR were calculated using GraphPad Prism and are expressed as the means Ϯ S.E.M. of n ϭ Ն4 experiments.
Data Accumulation and Statistical Analyses. For ligand binding studies in cell lines, varying concentrations of each of the compounds, ranging from 10 Ϫ12 to 10 Ϫ5 M, were added in duplicate within each experiment, and the individual molar IC 50 values were determined using GraphPad Prism. The displacement curves were plotted using a standard slope factor of 1.0, the K i values of the competing ligands were determined using the equation of Cheng and Prusoff (1973) , and the final data are presented as means Ϯ S.E.M. of n ϭ 4 or more experiments. In the functional studies, the IC 50 values of the antagonists for the concentration-dependent reversal of the action of the agonist, medetomidine, against forskolin-induced cAMP responses at the human ␣ 2C -AR were calculated using GraphPad Prism and are expressed as the means Ϯ S.E.M. of n ϭ 4 experiments. Differences between means of binding affinities and functional responses for individual ligands on the AR subtypes were analyzed by analysis of variance and Tukey's post hoc analysis test. When two means were compared, statistical analyses were done using Student's t test. Values were considered to be statistically significant when P Ͻ 0.05.
Results
Radioligand Binding Assay. Radioligand binding analyses of yohimbine (1), yohimbinic acid (2), the n ϭ 3 yohimbine dimer (3), and tethered yohimbine analogs (4-10) were performed in CHO cells stably expressing homogeneous populations of human ␣ 2A -, ␣ 2B -, and ␣ 2C -ARs. Structures of all compounds are provided in Fig. 1 . The binding affinities of the compounds are presented in Table 1 .
As described previously (Mustafa et al., 2005) , the rank order of binding affinities exhibited by yohimbine (1) on the human ␣ 2 -AR subtypes was ␣ 2C Ն ␣ 2A Ͼ ␣ 2B , with 2-and 7-fold higher binding affinities for the ␣ 2C -versus the ␣ 2A -and ␣ 2B -ARs. Interestingly, studies with yohimbinic acid (2) revealed that this compound exhibited a greatly decreased binding potency at the ␣ 2A -AR (345-fold) versus the ␣ 2B -AR (2-fold) and the ␣ 2C -AR (20-fold), compared with yohimbine. Furthermore, it was equipotent in binding to the ␣ 2B -and ␣ 2C -ARs, and its binding at the ␣ 2B -AR was 46-fold greater than its binding at the ␣ 2A -AR. Figure 2 shows the binding displacement curves for yohimbine (1) (A) and yohimbinic acid (2) (B) at the three ␣ 2 -AR receptor subtypes. The n ϭ 3 dimeric analog (3) was 18-and 68-fold selective in binding to the ␣ 2C -versus ␣ 2A -and ␣ 2B -AR subtypes ( Table 1 ). All of the tethered yohimbine analogs (4-10) exhibited significantly higher binding affinities at the ␣ 2C -versus ␣ 2A -and ␣ 2B -AR subtypes (Table 1 ). In particular, the benzyl carbamate alkyl amine (6), t-butyl carbamate alkyl amine (7), benzyl carboxy alkyl amine (9), and carboxy alkyl amine (10) analogs possessed binding affinities comparable with those of the parent molecule, yohimbine (1), at the ␣ 2C -AR (Table 1 ). The alkyl amine analog (8), however, was 32-fold less potent in binding to the ␣ 2C -AR compared with yohimbine (1). In addition, it was 129-and 316-fold less potent in binding to the ␣ 2A -and ␣ 2B -AR subtypes in comparison with yohimbine. The benzyl carbamate alkyl amine analog (6) and the t-butyl carbamate alkyl amine analog (7) were 11-and 59-fold and 3-and 33-fold selective in binding to the ␣ 2C -versus the ␣ 2A -and ␣ 2B -ARs, respectively (Table 1 ). The benzyl carboxy alkyl amine analog (9) and the carboxy alkyl amine analog (10) exhibited 43-and 1995-fold and 295-and 54-fold selectivities in binding to the ␣ 2C -versus ␣ 2A -and ␣ 2B -ARs, respectively. (Table 1) .
As has been observed with the yohimbine dimers (Lalchandani et al., 2002) , all of the tethered yohimbine analogs, with the exception of the monoglycine ester (4) and the carboxy TABLE 1 Binding affinities of yohimbine, yohimbinic acid, the n ϭ 3 yohimbine dimer, and tethered yohimbine analogs on human ␣ 2A -, ␣ 2B -, and ␣ 2C -AR subtypes that are stably expressed in CHO cells ͓ 3 H͔Rauwolscine was used as the radioligand in the equilibrium competition radioligand binding assays for the ␣ 2 -ARs, and the nonspecific binding was measured in the presence of 10 M phentolamine. pK i ϭ Ϫlog K i (K i was calculated according to the Cheng-Prusoff equation). See Materials and Methods. The data are means Ϯ S.E.M. of n ϭ 4 -6 experiments. Statistical analyses were carried out by one-way analysis of variance followed by Tukey's test (P Ͻ 0.05). (Table 1) . The binding affinities of yohimbine (1) and the two selected analogs, viz. the benzyl carbamate alkyl amine (6) and alkyl amine (8) analogs, were determined in HEK293 cells stably expressing homogeneous populations of human ␣ 1A -, ␣ 1B -, and ␣ 1D -ARs. Yohimbine and the selected analogs were found to bind with low affinities at all three ␣ 1 -AR subtypes ( Table  2 ). The binding affinities of yohimbine (1), the benzyl carbamate alkyl amine (6), and the alkyl amine (8) analog for the ␣ 2C -AR subtype were at least 224-, 562-, and 100-fold greater than those on the ␣ 1 -AR subtypes, respectively (compare data in Tables 1 and 2 ). Taken collectively, the data confirm the binding selectivity of these ligands for the ␣ 2C -AR subtype.
cAMP Response Element-Luciferase Reporter Gene Assay. The functional responses of yohimbine and selected tethered analogs in the human ␣ 2A -and ␣ 2C -ARs expressing CHO cells were determined using 6 CRE-LUC plasmid. The assays with both ␣ 2A -and ␣ 2C -ARs were conducted using the non-subtype-selective ␣ 2 -AR agonist, medetomidine, to block the cAMP changes induced by the adenylyl cyclase activator, forskolin. The concentration of forskolin (3-5 M) for the assays was chosen such that it produced at least a 7-to 10-fold increase over basal levels. Basal values (solvent control) were subtracted from the forskolin values, and the re- 
TABLE 2
Binding affinities of yohimbine and selected tethered yohimbine analogs on human ␣ 1A -, ␣ 1B -, and ␣ 1D -AR subtypes that are stably expressed in HEK293 cells ͓ 3 H͔Prazosin was used as the radioligand in the equilibrium competition radioligand binding assays for the ␣ 1 -ARs, and the nonspecific binding was measured in the presence of 10 M phentolamine. pK i ϭ Ϫlog K i (K i was calculated according to the Cheng-Prusoff equation). See Materials and Methods. The data are means Ϯ S.E.M. of n ϭ 4 -6 experiments. Statistical analyses were carried out by one-way analysis of variance followed by Tukey's test (P Ͻ 0.05). (Fig. 3A) . As shown, medetomidine showed inhibition of the forskolin-induced cAMP response at low concentrations (0.0001-0.01 M), whereas higher concentrations (0.1-10 M) reversed the inhibition of luciferase activity observed at the lower medetomidine concentrations. The maximal inhibition obtained for medetomidine was 56% at 0.01 M. Medetomidine alone (in the absence of forskolin) increased cAMP levels by 17% when tested at a concentration of 10 M (data not shown).
Compound
In cells expressing the ␣ 2C -AR, however, medetomidine caused a concentration-dependent reduction in the forskolininduced cAMP activity at all concentrations tested (0.01-10 M). The maximal inhibition obtained for medetomidine was 70% at 1 M (Fig. 3B) . A higher concentration of medetomidine (10 M) did not cause any further decrease in the forskolin-induced cAMP. Medetomidine alone (in the absence of forskolin) did not show an increase in cAMP levels when tested at a concentration of 1 M (data not shown). These results may suggest a G i (inhibitory) to G s (stimulatory) coupling change only for the ␣ 2A -AR at higher agonist concentrations (S. G. Lalchandani and D. R. Feller, unpublished data; Pepperl and Regan, 1993; Eason et al., 1992) .
For functional studies with yohimbine and selected yohimbine analogs at the ␣ 2A -and ␣ 2C -ARs, the concentration of medetomidine was chosen such that it produced a submaximal (around 50 -70%) inhibition of the forskolin response in these subtypes. From our data in the previous set of experiments (Fig. 3) , the medetomidine concentration was fixed at 0.01 M for the ␣ 2A -AR whereas it was fixed at 1 M for the ␣ 2C -AR. The agonist ligand, medetomidine, was added directly to the medium 20 min before the addition of forskolin and then allowed to incubate for 4 h. Yohimbine analogs selected for functional testing at the ␣ 2 -ARs included the benzyl carbamate alkyl amine (6) and the alkyl amine (8) analogs. Concentrations of yohimbine (1), the benzyl carbamate alkyl amine (6), and the alkyl amine analog (8) were fixed at 0.1, 0.1, and 1 M, respectively, for the ␣ 2A -AR assays whereas they were varied from 0.001 to 10 M for the ␣ 2C -AR assays. These compounds were added 20 min before the addition of medetomidine.
On the ␣ 2A -AR, medetomidine (0.01 M) inhibited forskolin-induced cAMP changes and the mean inhibition produced was 56 Ϯ 2% for n ϭ 5 experiments (Fig. 4) . As noted in the graph, the mean percent inhibition produced after preincubation with yohimbine (1) (0.1 M), the benzyl carbamate alkyl amine analog (6) (0.1 M), and the alkyl amine analog (8) (1 M) were 14.2, 54, and 53%, respectively. Thus, the changes in luciferase activity produced by medetomidine were blocked by yohimbine (1) (0.1 M). Neither of the two analogs, however, blocked the medetomidine inhibition of forskolin-induced luciferase activity at the chosen concentrations. Controls of yohimbine and the two tethered yohimbine analogs were included for comparison (Fig. 4) . In the pres- at ASPET Journals on November 13, 2017 jpet.aspetjournals.org ence of forskolin, none of the test antagonist ligands produced agonist activity at the concentrations tested (data not shown).
A graphical representation of the concentration-dependent effects of yohimbine (1), the benzyl carbamate alkyl amine analog (6), and the alkyl amine analog (8), for the reversal of the forskolin-induced cAMP changes by medetomidine at the ␣ 2C -ARs is provided in Fig. 5, A, B , and C, respectively. As can be seen from these graphs, the mean percentage inhibition produced by medetomidine (1 M) at the ␣ 2C -AR was 70 Ϯ 2% for n ϭ 4 experiments. Controls of yohimbine and the two tethered analogs were included for comparison (Fig.  5) . In the presence of forskolin, none of the test antagonist ligands produced agonist activity at the highest concentration tested (data not shown).
A comparison of the experimentally determined functional antagonist activities for yohimbine and the selected tethered yohimbine analogs at human ␣ 2A -and ␣ 2C -ARs stably expressed in CHO cells is given in Fig. 6 . As shown, significant differences were observed in the abilities of the benzyl carbamate alkyl amine analog (6) and the alkyl amine analog (8) to reverse the medetomidine inhibition of forskolin-induced cAMP elevations at the ␣ 2A -and ␣ 2C -AR subtypes, when used at the same concentration. Concentrations used were yohimbine (1) (0.1 M), yohimbine benzyl carbamate alkyl amine analog (6) (0.1 M), and yohimbine alkyl amine analog (8) (1 M). It is important to note here that the two tethered analogs were able to reverse the medetomidine inhibition of the forskolin response on the ␣ 2C -but not on the ␣ 2A -AR subtype. Furthermore, despite the inhibition produced by medetomidine being less in the ␣ 2A -AR (56 Ϯ 2%) versus the ␣ 2C -AR subtype (70 Ϯ 2%), blockade of the medetomidine responses were only observed with yohimbine on the ␣ 2A -AR. Taken collectively, these data indicate the ␣ 2C -versus ␣ 2A -AR selectivity of the selected tethered yohimbine analogs. Table 3 shows the pIC 50 values of yohimbine and its analogs for the reversal of the medetomidine action against forskolin-induced cAMP responses at the human ␣ 2C -AR, along with their binding affinities (pK i values) at the same receptor subtype. A linear regression analysis of the reversal response for each antagonist was used to determine the IC 50 values for the antagonists. For this purpose, the luciferase response of forskolin alone was used as 100%, whereas that of forskolin in the presence of the agonist, medetomidine, was used as 0%. Although pK b values would have served as a better comparison, the functional potencies (pIC 50 values) of yohimbine and the benzyl carbamate alkyl amine analog at the ␣ 2C -ARs were not found to be statistically different from the experimentally determined binding affinities (pK i values). In addition, the rank order of functional and binding potencies for the three compounds remained the same: yohimbine benzyl carbamate alkyl amine (6) Ն yohimbine (1) Ͼ yohimbine alkyl amine (8).
Discussion
G protein-coupled receptors, traditionally considered to function as monomeric proteins, have now been proposed to exist as dimers or even higher-structure oligomers (Angers et al., 2002) . The physiological significance of such dimerization and its implications in ligand pharmacology and, potentially, for drug design remain to be fully understood. However, there have been efforts to improve potency and/or subtypeselectivity by use of bivalent or dimeric ligands. Lalchandani et al. (2002) demonstrated that dimers of the potent and jpet.aspetjournals.org relatively nonselective ␣ 2 -AR antagonist yohimbine consisting of two pharmacophores linked through a spacer, exhibited a higher degree of ␣ 2 -AR subtype-selectivity than the parent molecule. The authors used the bivalent ligand approach, which is based on the concept that a bivalent ligand would first undergo univalent binding followed by binding of the second pharmacophore to a recognition site on a neighboring receptor. Thus, the bivalent ligand would exhibit a greater potency than that derived from the sum of its monovalent counterparts (Portoghese, 2001) . In the yohimbine dimer study, the addition of methylene and methylene-diglycine spacer linkages produced analogs that were potent and selective ␣ 2C -AR ligands. It was proposed that one pharmacophore (or one yohimbine molecule) binds to the ligand receptor site, whereas the second pharmacophore may bind to either 1) an adjacent site of the ligand binding pocket, or transmembrane domain, or one of the extracellular loops on the same receptor or 2) a ligand-binding site or a recognition site on a neighboring receptor. With shorter spacer arms, however, an interaction of the second pharmacophore with an adjacent receptor molecule (dimer) seems less probable. Interestingly, none of the analogs in the yohimbine dimer series surpassed the affinity of the parent compound, yohimbine.
Recently, Mustafa et al. (2005) demonstrated that monomeric analogs of yohimbine, even in the absence of the second pharmacophore (or the second yohimbine molecule), with appendages or tethers of varying nature and composition retained high binding potencies, like that of the dimeric analogs, at the human ␣ 2C -AR. In fact, one of the tethered analogs, viz. the benzyl carboxy alkyl amine analog (9), displayed a greater binding affinity at the ␣ 2C -AR than the parent compound, yohimbine (Table 1 ). This result suggests that high binding affinities, previously observed with the dimeric ligands, may not be attributable to receptor dimerization and clustering, as proposed earlier (Lalchandani et al., 2002) . The main focus of our study was to determine whether the second pharmacophore was essential for the ␣ 2C -AR selectivity of the yohimbine dimers; i.e., would truncating dimeric analogs to tethered analogs still retain the ␣ 2C -AR selectivity? For this purpose, we have extended the evaluation of the tethered yohimbine analogs (Mustafa et al., 2005) to all human ␣ 2 -AR subtypes. The importance of the charge of the tethers, in potency and/or subtype selectivity, was investigated using neutral, basic, and acidic functional groups.
In the yohimbine dimer series, the n ϭ 3 and n ϭ 24 dimers exhibited the greatest ␣ 2C -AR selectivity (Lalchandani et al., 2002) . In functional assays, the n ϭ 3 dimeric analog was found to be more potent as well as more ␣ 2C -AR selective than the n ϭ 24 dimer. This finding, along with the idea that the n ϭ 3 dimer would better fit the criteria for drug-like status (Lipinski et al., 1997) compared with the n ϭ 24 dimer, led us to design the structure of the tethered analogs using the n ϭ 3 yohimbine dimer as a standard. In our study, we have found the n ϭ 3 dimer (3) to be 18-and 68-fold selective in binding to the ␣ 2C -versus the ␣ 2A -and ␣ 2B -ARs, respectively.
Our data for the parent compound, yohimbine (1) ( Table 1 ; Fig. 2A ), agree with those reported in the literature (Bylund et al., 1992; Lalchandani et al., 2002) . We have also evaluated yohimbinic acid (2), a nontethered structural analog of yohimbine, for its binding to the ␣ 2 -ARs. Interestingly, there are no reports published in the literature on the interaction of yohimbinic acid with the ARs. Data from this study showed that a single structural change in the yohimbine molecule (changing the methyl ester at the C-16 carbonyl of yohimbine to an acid functionality), yielding yohimbinic acid, had a significant impact on its binding affinities at the ␣ 2 -AR subtypes. Yohimbinic acid exhibited greatly decreased binding potency at the ␣ 2A -AR (345-fold) versus the ␣ 2B -AR (2-fold) and the ␣ 2C -AR (20-fold), compared with yohimbine (Table 1 ; Fig. 2B ). Furthermore, it was equipotent in binding to the ␣ 2B -and ␣ 2C -ARs, and its binding at the ␣ 2B -AR was 46-fold greater than its binding at the ␣ 2A -AR. It is noteworthy that yohimbinic acid is a selective ␣ 2C -versus ␣ 2A -AR ligand, with fold selectivity being ϳ32-fold.
In the present study, as in the study reported previously (Lalchandani et al., 2000) , the n ϭ 3 dimer (3) did not surpass the binding affinity of yohimbine. In addition, although all of the tethered yohimbine analogs exhibited higher binding affinities at the ␣ 2C -versus ␣ 2A -and ␣ 2B -AR subtypes (Table  1) , only one of the tethered analogs, the benzyl carboxy alkyl amine analog (9), exceeded the affinity of the parent compound, yohimbine (1) at the ␣ 2C -AR. The benzyl carbamate alkyl amine (6), the t-butyl carbamate alkyl amine (7) and the carboxy alkyl amine (10) analogs possessed binding affinities comparable with those of the parent molecule, yohimbine, at the ␣ 2C -AR. The alkyl amine analog (8) was 32-fold less potent in binding to the ␣ 2C -AR compared with yohimbine; however, it was 129-and 316-fold less potent in binding to the ␣ 2A -and ␣ 2B -AR subtypes in comparison with yohimbine (Table 1) .
In regards to ␣ 2C -AR selectivities of the tethered analogs, the benzyl carbamate alkyl amine analog (6) and the alkyl amine analog (8) possessed affinities for the ␣ 2C -AR, which were 11-and 59-fold and 7-and 72-fold greater than The concentration of forskolin (3-5 M) was chosen such that it produced at least a 7-to 10-fold increase over basal levels. The concentration of medetomidine was chosen such that it produced at least a 50% inhibition of the forskolin-induced cAMP response. The mean inhibition produced with the ␣ 2A -ARs was 56 Ϯ 2% for n ϭ 5 experiments, whereas at the ␣ 2C -ARs, the mean inhibition was 70 Ϯ 2% for n ϭ 4 experiments. ‫,ء‬ response at the ␣ 2C -ARs is different from the response at ␣ 2A -ARs (P Ͻ 0.05 using Student's t test). their binding to the ␣ 2A -and ␣ 2B -ARs, respectively. The benzyl carboxy alkyl amine analog (9) and the carboxy alkyl amine analog (10) exhibited a 43-and 1995-fold and 295-and 54-fold selectivity in binding to the ␣ 2C -versus ␣ 2A -and ␣ 2B -ARs, respectively. Whether this enhanced ␣ 2C -AR selectivity observed with the benzyl carboxy alkyl amine analog and the carboxy alkyl amine analog represents additional interactions with basic residues in or around the ligand-binding pocket needs to be further investigated. Our binding results demonstrate that the tethered yohimbine analogs were more ␣ 2C -AR selective than the n ϭ 3 dimer, suggesting that the second pharmacophore is not necessary to achieve the ␣ 2 -AR subtype selectivity with this chemical scaffold. We have also confirmed the functional antagonist activities of select compounds from this series at the ␣ 2A -and ␣ 2C -ARs using luciferase reporter gene assays (Figs. 3-5) . Data from these assays also revealed that there is an ␣ 2C -versus ␣ 2A -AR selectivity for all of the tethered analogs tested (Fig. 6 ).
In conclusion, this study has yielded tethered analogs of yohimbine as selective and potent ␣ 2C -AR antagonists. This series of compounds may be interpreted as a novel series of yohimbine analogs with varying substitutions at the C-16 carbonyl position, yielding ligands with differing degrees of ␣ 2C -AR selectivity. The results also help to understand the underlying basis for the ␣ 2C -AR subtypeselectivity previously observed with the dimeric analogs and suggest the following: 1) The second pharmacophoric group, i.e., the second yohimbinic acid molecule, may not be essential for the ␣ 2C -AR subtype-selectivity previously seen with the dimeric analogs. We have shown that tethered yohimbine analogs, like dimers, exhibit ␣ 2C -AR selectivity. 2) Thus, an interaction of the second pharmacophoric group with either one of the extracellular loops on the same receptor or with a recognition site on a neighboring receptor, an adjacent site of the ligand-binding pocket on a single receptor, or an adjacent receptor molecule may not be the underlying mechanism(s) required for the observed synergy witnessed with the dimeric compounds, as proposed previously (Portoghese, 2001; Lalchandani et al., 2002) . 3) Instead, we propose that differences in the physicochemical properties of the amino acid residues (e.g., steric or hydrogen bonding) constituting and surrounding the putative ligand-binding domain, are unique in each subtype, and this distinction can be exploited to develop receptor subtype selectivity. 4) Systematic alterations of the nature of the tether in a ligand on the yohimbine molecule scaffold may be crucial in maximizing unique ligand-receptor interactions in each ␣ 2 -AR subtype, and further optimization of the tether length and/or composition may possibly lead to the design of ␣ 2C -AR ligands that will be more potent than yohimbine. An additional advantage of using the monovalent ligand approach is that, compared with the dimeric compounds, the tethered analogs would have improved physicochemical and pharmacokinetic parameters (Lipinski et al., 1997) . 
